Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)

NCT06973629 is registered in ClinicalTrials.gov with Brainstorm-Cell Therapeutics as lead sponsor.

NCT NCT06973629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
Brainstorm-Cell Therapeutics
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
May 1, 2029
Enrollment
200 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, amyotrophic lateral sclerosis (als)